Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart A Westerman

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Cancer Cell|April 7, 2009
ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcomeSidong Huang, Jamila Laoukili, Mirjam T Epping, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|May 5, 2019
The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target CompensationHamza Saleem, U Kulsoom Abdul, Asli Küçükosmanoglu, et al.
Neuro-Oncology Practice|August 15, 2025
Severe temozolomide-induced thrombocytopenia is linked to increased healthcare utilization in glioblastoma and disproportionally impacts female patientsLeon van Hout, Alessia D Borgo, Nienke Grun, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 7, 2021
CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [<sup>68</sup>Ga]Ga-Pentixafor /[<sup>177</sup>Lu]Lu-PentixatherSarah M Jacobs, Pieter Wesseling, Bart de Keizer, et al.
Anticancer Research|July 3, 2019
To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical PharmacologyBtissame El Hassouni, Giulia Mantini, Giovanna Li Petri, et al.
Molecular Oncology|October 17, 2024
The translatome of glioblastomaFleur M G Cornelissen, Zhaoren He, Edward Ciputra, et al.
Neuro-Oncology Advances|July 17, 2023
Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategiesMegan Houweling, Anna Giczewska, Kulsoom Abdul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2024
A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive InteractionsAsli Küçükosmanoglu, Silvia Scoarta, Megan Houweling, et al.
Molecular Cancer Therapeutics|August 1, 2025
Combined inactivation of MEK and mTOR can lead to synergistic cell death in glioblastoma models and associates with NF1-deficiency and a mesenchymal subtypeFleur M G Cornelissen, Yoran Broersma, Ravi S Narayan, et al.
Molecular Cancer Therapeutics|August 20, 2025
Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal SubtypeFleur M G Cornelissen, Yoran Broersma, Ravi S Narayan, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Cancer Cell|April 7, 2009
ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcomeSidong Huang, Jamila Laoukili, Mirjam T Epping, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|May 5, 2019
The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target CompensationHamza Saleem, U Kulsoom Abdul, Asli Küçükosmanoglu, et al.
Neuro-Oncology Practice|August 15, 2025
Severe temozolomide-induced thrombocytopenia is linked to increased healthcare utilization in glioblastoma and disproportionally impacts female patientsLeon van Hout, Alessia D Borgo, Nienke Grun, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 7, 2021
CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [<sup>68</sup>Ga]Ga-Pentixafor /[<sup>177</sup>Lu]Lu-PentixatherSarah M Jacobs, Pieter Wesseling, Bart de Keizer, et al.
Anticancer Research|July 3, 2019
To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical PharmacologyBtissame El Hassouni, Giulia Mantini, Giovanna Li Petri, et al.
Molecular Oncology|October 17, 2024
The translatome of glioblastomaFleur M G Cornelissen, Zhaoren He, Edward Ciputra, et al.
Neuro-Oncology Advances|July 17, 2023
Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategiesMegan Houweling, Anna Giczewska, Kulsoom Abdul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2024
A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive InteractionsAsli Küçükosmanoglu, Silvia Scoarta, Megan Houweling, et al.
Molecular Cancer Therapeutics|August 1, 2025
Combined inactivation of MEK and mTOR can lead to synergistic cell death in glioblastoma models and associates with NF1-deficiency and a mesenchymal subtypeFleur M G Cornelissen, Yoran Broersma, Ravi S Narayan, et al.
Molecular Cancer Therapeutics|August 20, 2025
Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal SubtypeFleur M G Cornelissen, Yoran Broersma, Ravi S Narayan, et al.
Pageof 5